BOSTON, Massachusetts — March 4, 2026 — Leads & Copy — X4 Pharmaceuticals (Nasdaq: XFOR) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026, at 10:00 a.m. ET in Miami, FL.
A live and archived webcast will be available on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.
X4 Pharmaceuticals focuses on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. X4 has developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication, leveraging expertise in diseases of the immune system and CXCR4 biology. The Company is conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts.
Source: X4 Pharmaceuticals
